Updated October 3, 2026
A bipartisan coalition of state attorneys general is administering consumer claims tied to settlements in federal antitrust litigation over generic drug pricing. The states allege that manufacturers coordinated prices, bids, and market allocation for numerous generic medicines. Generic drugs contain the same active ingredient as a brand-name medicine and are commonly filled at pharmacies after a doctor writes a prescription. The current claim program covers qualifying purchases of drugs identified on the official AGGenericDrugs.com list from May 2009 through December 2019. Consumers must use the official list and claim form because not every generic medicine, purchase, state, payer, or transaction is necessarily covered. Claims are due March 8, 2027. Earlier settlements with Apotex, Heritage, Bausch, Lannett, and Glenmark contributed more than $96 million. On October 1, 2026, the states filed a new proposed $400 million settlement with Sandoz Inc. and Fougera Pharmaceuticals. That Sandoz agreement requires court approval and includes consumer, government, business, litigation-cost, and administration allocations. It does not establish a fixed individual payment.
Submit purchase information through the official process by March 8, 2027. The administrator applies the drug list, jurisdiction rules, and approved allocation method. No minimum or maximum personal payment is promised here.
Settlement totals include several defendants and allocations. An individual share can depend on eligible spending, claim volume, available consumer funds, and court orders.
The October 1, 2026 agreement adds proposed monetary relief and compliance obligations but does not convert the states' allegations into findings or guarantee added money to a particular claimant.
The program provides restitution from manufacturer settlements, but it does not promise a fixed dollar amount per consumer. Distribution depends on the approved funds, eligible drugs and purchases, valid claims, allocation rules, and permitted deductions. The October 2026 Sandoz proposal totals $400 million over seven years, with about 70% designated as restitution for consumers, government entities, and certain businesses and about 30% designated for litigation and related state costs. Sandoz denies the allegations, and its settlement remains subject to court approval.
Official settlement site: State Attorneys General Generic Drugs Settlement. Class Action Pulse is not the settlement administrator or a law firm — always verify eligibility, deadlines, and payout details through the official source above.
Check your eligibility and get help understanding your claim. It's free and takes under a minute.
No. The official site maintains a covered-drug list, and purchases must also satisfy the applicable date, jurisdiction, and claim requirements.
No fixed individual amount has been established in the sources reviewed. Payment depends on the approved distribution, eligible purchases, valid claims, and available consumer restitution.
No. The states filed the proposed agreement and a motion for preliminary approval on October 1, 2026. Court review and later approval steps remain.
No. The court filing states that Sandoz denies the allegations. The proposed settlement would resolve specified state claims without a trial finding.
It is a medicine approved to use the same active ingredient as a brand-name drug. The dispute concerns alleged competition and pricing conduct, not a claim that generic medicines are inherently unsafe.
No. Class Action Pulse is not a law firm or settlement administrator and cannot guarantee eligibility or payment. Rust Consulting operates the official claim process for the states.
